MedCap AB (publ) (STO:MCAP)
Sweden · Delayed Price · Currency is SEK 551.00
+5.00 (0.92%)
Aug 14, 2026, 5:29 PM CET
MedCap AB Financials Overview
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 2,257 | 2,110 | 1,807 | 1,589 | 1,124 | 926.3 |
Revenue Growth | 18.58% | 16.73% | 13.74% | 41.37% | 21.34% | 11.87% |
Gross Profit Gross Profit Growth | 1,340 | 1,238 | 1,058 | 928.3 | 677.2 | 568.6 |
Operating Income Operating Income Growth | 317.2 | 288.7 | 240.8 | 216.2 | 149.1 | 103.8 |
Net Income Net Income Growth | 240.6 | 219.8 | 207.4 | 172.2 | 117.6 | 96.5 |
Earnings Per Share EPS Growth | 16.07 | 14.67 | 14.00 | 11.60 | 7.90 | 6.50 |
EPS Growth | 20.81% | 4.80% | 20.66% | 46.84% | 21.54% | 53.18% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Assistive Tech Assistive Tech Growth | 1,047 | 981.8 | 767.2 | 590.5 | 270 | - |
Medtech Medtech Growth | 722.6 | 689.6 | 607.7 | 511.7 | 444.3 | - |
Specialty Pharma Specialty Pharma Growth | 486.2 | 436.6 | 431.8 | 485.3 | 397 | 316.8 |
Revenue (Total) Revenue (Total) Growth | 2,319 | 2,151 | 1,856 | 1,615 | 1,154 | 949.6 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 286.3 | 370.4 | 370.1 | 188.2 | 236.2 | 139.7 |
Total Debt Total Debt Growth | 457.6 | 482.9 | 358 | 261.2 | 340 | 256.9 |
Net Cash (Debt) Net Cash Growth | -171.3 | -112.5 | 12.1 | -73 | -103.8 | -117.2 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -11.43 | -7.50 | 0.81 | -4.91 | -7.01 | -7.92 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 387.3 | 342.7 | 360 | 228 | 85.5 | 116.3 |
Capital Expenditures CapEx Growth | -23.9 | -25.7 | -41.8 | -22.1 | -26.3 | -45.3 |
Free Cash Flow Free Cash Flow Growth | 363.4 | 317 | 318.2 | 205.9 | 59.2 | 71 |
Free Cash Flow Growth | 21.87% | -0.38% | 54.54% | 247.80% | -16.62% | -31.66% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 59.38% | 58.67% | 58.52% | 58.42% | 60.25% | 61.38% |
Operating Margin | 14.05% | 13.69% | 13.32% | 13.61% | 13.26% | 11.21% |
Pretax Margin | 13.90% | 13.70% | 14.47% | 13.99% | 13.52% | 12.63% |
Profit Margin | 10.66% | 10.42% | 11.48% | 10.84% | 10.46% | 10.42% |
FCF Margin | 16.10% | 15.03% | 17.61% | 12.96% | 5.27% | 7.66% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 34.30 | 37.66 | 42.91 | 29.02 | 27.26 | 27.31 |
Forward PE | 24.92 | 31.55 | 39.28 | 25.95 | 25.95 | 25.95 |
P/FCF Ratio | 22.71 | 26.11 | 27.97 | 24.27 | 54.15 | 37.12 |
PS Ratio | 3.66 | 3.92 | 4.92 | 3.15 | 2.85 | 2.85 |